Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma

Cheng Lung Ma, Cheng Lung Hsu, Ming Heng Wu, Chun Te Wu, Cheng Chia Wu, Jiann Jyh Lai, Yuh Shan Jou, Chun Wei Chen, Shuyuan Yeh, Chawnshang Chang

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Background & Aims: Androgen effects on hepatocellular carcinoma (HCC) remain controversial and androgen ablation therapy to treat HCC also leads to inconsistent results. Here we examine androgen receptor (AR) roles in hepatocarcinogenesis using mice lacking AR in hepatocytes. Methods: By using the Cre-Lox conditional knockout mice model injected with carcinogen, we examined the AR roles in hepatocarcinogenesis. We also tested the possible roles of AR in cellular oxidative stress and DNA damage sensing/repairing systems. By using AR degrading compound, ASC-J9, or AR-small interference RNA, we also examined the therapeutic potentials of targeting AR in HCC. Results: We found AR expression was increased in human HCC compared with normal livers. We also found mice lacking hepatic AR developed later and less HCC than their wild-type littermates with comparable serum testosterone in both male and female mice. Addition of functional AR in human HCC cells also resulted in the promotion of cell growth in the absence or presence of 5α-dihydrotestosterone. Mechanistic dissection suggests that AR may promote hepatocarcinogenesis via increased cellular oxidative stress and DNA damage, as well as suppression of p53-mediated DNA damage sensing/repairing system and cell apoptosis. Targeting AR directly via either AR-small interference RNA or ASC-J9 resulted in suppression of HCC in both ex vivo cell lines and in vivo mice models. Conclusions: Our data point to AR, but not androgens, as a potential new and better therapeutic target for the battle of HCC.

Original languageEnglish
JournalGastroenterology
Volume135
Issue number3
DOIs
Publication statusPublished - Sep 2008
Externally publishedYes

Fingerprint

Androgen Receptors
Hepatocellular Carcinoma
Therapeutics
Androgens
DNA Damage
RNA Interference
Oxidative Stress
Dihydrotestosterone
Liver
Knockout Mice
Carcinogens
Testosterone
Dissection
Hepatocytes
Apoptosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma. / Ma, Cheng Lung; Hsu, Cheng Lung; Wu, Ming Heng; Wu, Chun Te; Wu, Cheng Chia; Lai, Jiann Jyh; Jou, Yuh Shan; Chen, Chun Wei; Yeh, Shuyuan; Chang, Chawnshang.

In: Gastroenterology, Vol. 135, No. 3, 09.2008.

Research output: Contribution to journalArticle

Ma, Cheng Lung ; Hsu, Cheng Lung ; Wu, Ming Heng ; Wu, Chun Te ; Wu, Cheng Chia ; Lai, Jiann Jyh ; Jou, Yuh Shan ; Chen, Chun Wei ; Yeh, Shuyuan ; Chang, Chawnshang. / Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma. In: Gastroenterology. 2008 ; Vol. 135, No. 3.
@article{00c369054b654f8e917c451570f5a818,
title = "Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma",
abstract = "Background & Aims: Androgen effects on hepatocellular carcinoma (HCC) remain controversial and androgen ablation therapy to treat HCC also leads to inconsistent results. Here we examine androgen receptor (AR) roles in hepatocarcinogenesis using mice lacking AR in hepatocytes. Methods: By using the Cre-Lox conditional knockout mice model injected with carcinogen, we examined the AR roles in hepatocarcinogenesis. We also tested the possible roles of AR in cellular oxidative stress and DNA damage sensing/repairing systems. By using AR degrading compound, ASC-J9, or AR-small interference RNA, we also examined the therapeutic potentials of targeting AR in HCC. Results: We found AR expression was increased in human HCC compared with normal livers. We also found mice lacking hepatic AR developed later and less HCC than their wild-type littermates with comparable serum testosterone in both male and female mice. Addition of functional AR in human HCC cells also resulted in the promotion of cell growth in the absence or presence of 5α-dihydrotestosterone. Mechanistic dissection suggests that AR may promote hepatocarcinogenesis via increased cellular oxidative stress and DNA damage, as well as suppression of p53-mediated DNA damage sensing/repairing system and cell apoptosis. Targeting AR directly via either AR-small interference RNA or ASC-J9 resulted in suppression of HCC in both ex vivo cell lines and in vivo mice models. Conclusions: Our data point to AR, but not androgens, as a potential new and better therapeutic target for the battle of HCC.",
author = "Ma, {Cheng Lung} and Hsu, {Cheng Lung} and Wu, {Ming Heng} and Wu, {Chun Te} and Wu, {Cheng Chia} and Lai, {Jiann Jyh} and Jou, {Yuh Shan} and Chen, {Chun Wei} and Shuyuan Yeh and Chawnshang Chang",
year = "2008",
month = "9",
doi = "10.1053/j.gastro.2008.05.046",
language = "English",
volume = "135",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma

AU - Ma, Cheng Lung

AU - Hsu, Cheng Lung

AU - Wu, Ming Heng

AU - Wu, Chun Te

AU - Wu, Cheng Chia

AU - Lai, Jiann Jyh

AU - Jou, Yuh Shan

AU - Chen, Chun Wei

AU - Yeh, Shuyuan

AU - Chang, Chawnshang

PY - 2008/9

Y1 - 2008/9

N2 - Background & Aims: Androgen effects on hepatocellular carcinoma (HCC) remain controversial and androgen ablation therapy to treat HCC also leads to inconsistent results. Here we examine androgen receptor (AR) roles in hepatocarcinogenesis using mice lacking AR in hepatocytes. Methods: By using the Cre-Lox conditional knockout mice model injected with carcinogen, we examined the AR roles in hepatocarcinogenesis. We also tested the possible roles of AR in cellular oxidative stress and DNA damage sensing/repairing systems. By using AR degrading compound, ASC-J9, or AR-small interference RNA, we also examined the therapeutic potentials of targeting AR in HCC. Results: We found AR expression was increased in human HCC compared with normal livers. We also found mice lacking hepatic AR developed later and less HCC than their wild-type littermates with comparable serum testosterone in both male and female mice. Addition of functional AR in human HCC cells also resulted in the promotion of cell growth in the absence or presence of 5α-dihydrotestosterone. Mechanistic dissection suggests that AR may promote hepatocarcinogenesis via increased cellular oxidative stress and DNA damage, as well as suppression of p53-mediated DNA damage sensing/repairing system and cell apoptosis. Targeting AR directly via either AR-small interference RNA or ASC-J9 resulted in suppression of HCC in both ex vivo cell lines and in vivo mice models. Conclusions: Our data point to AR, but not androgens, as a potential new and better therapeutic target for the battle of HCC.

AB - Background & Aims: Androgen effects on hepatocellular carcinoma (HCC) remain controversial and androgen ablation therapy to treat HCC also leads to inconsistent results. Here we examine androgen receptor (AR) roles in hepatocarcinogenesis using mice lacking AR in hepatocytes. Methods: By using the Cre-Lox conditional knockout mice model injected with carcinogen, we examined the AR roles in hepatocarcinogenesis. We also tested the possible roles of AR in cellular oxidative stress and DNA damage sensing/repairing systems. By using AR degrading compound, ASC-J9, or AR-small interference RNA, we also examined the therapeutic potentials of targeting AR in HCC. Results: We found AR expression was increased in human HCC compared with normal livers. We also found mice lacking hepatic AR developed later and less HCC than their wild-type littermates with comparable serum testosterone in both male and female mice. Addition of functional AR in human HCC cells also resulted in the promotion of cell growth in the absence or presence of 5α-dihydrotestosterone. Mechanistic dissection suggests that AR may promote hepatocarcinogenesis via increased cellular oxidative stress and DNA damage, as well as suppression of p53-mediated DNA damage sensing/repairing system and cell apoptosis. Targeting AR directly via either AR-small interference RNA or ASC-J9 resulted in suppression of HCC in both ex vivo cell lines and in vivo mice models. Conclusions: Our data point to AR, but not androgens, as a potential new and better therapeutic target for the battle of HCC.

UR - http://www.scopus.com/inward/record.url?scp=51249105211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51249105211&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2008.05.046

DO - 10.1053/j.gastro.2008.05.046

M3 - Article

C2 - 18639551

AN - SCOPUS:51249105211

VL - 135

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -